SCHEMBL29927199

SCHEMBL29927199

C[C@H]1CN(C(=O)OCc2ccccc2)CCN1CC1CCN(CC2(F)CCN(C(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.45
PDK2 Q15119 1/20 0.45
PDK3 Q15120 1/20 0.45
PDK4 Q16654 1/20 0.45
KDM1A O60341 4/20 0.42
YAP1 P46937 2/20 0.40
HTT P42858 1/20 0.40
PARP1 P09874 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
CHRM4 P08173 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
CYP2C19 P33261 1/20 0.38
TACR1 P25103 1/20 0.38
GRIN2B Q13224 1/20 0.38
GPR119 Q8TDV5 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29927921 0.91 PDK1 (0.43) PDK1PDK2PDK3PDK4KDM1A
SCHEMBL29927865 0.89 PDK1 (0.51) PDK1PDK2PDK3PDK4KDM1A
SCHEMBL30706025 0.88 PDK1 (0.51) PDK1PDK2PDK3PDK4YAP1
SCHEMBL26927558 0.88 PDK1 (0.51) PDK1PDK2PDK3PDK4YAP1
SCHEMBL30731906 0.88 PDK1 (0.51) PDK1PDK2PDK3PDK4YAP1
SCHEMBL30706191 0.88 PDK1 (0.51) PDK1PDK2PDK3PDK4YAP1
SCHEMBL29928031 0.87 PDK1 (0.43) PDK1PDK2PDK3PDK4KDM1A
SCHEMBL29132254 0.86 KDM4E (0.35) KDM1AKDM4EPKMGPR119
SCHEMBL29927520 0.85 PDK1 (0.51) PDK1PDK2PDK3PDK4YAP1
SCHEMBL27162604 0.84 KDM1A (0.51) PDK1PDK2PDK3PDK4KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559506-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-24 US disclosed
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-10-31 US disclosed
US-11981683-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-05-14 US disclosed
EP-4308557-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2024-01-24 EP disclosed
CN-117321046-A Indazole-based compounds and related methods of use 阿维纳斯企业公司 2023-12-29 CN disclosed
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-30 US disclosed
WO-2022198112-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885
US-12559506-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, CLK2 PDK1 2125/4885PDK2 1878/4885PDK3 1663/4885
US-11981683-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.